$MYGN News

Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $3

Myriad Genetics: Strong Oncology Demand, But Monetization Breaks Down

Myriad Genetics, Inc. 2026 Q2 - Results - Earnings Call Presentation

TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4

Myriad Genetics Stock Drops Sharply After Hours: What Investors Need to Know

Myriad Genetics, Inc. (MYGN) Q2 2026 Earnings Call Transcript

Myriad Genetics (NASDAQ:MYGN) Plunges 26% After Fiscal Q2 Revenue and EPS Miss, Slashes Full-Year Guidance

Myriad Genetics Lowers FY2026 Sales Guidance from $860.000M-$880.000M to $770.000M-$790.000M vs $863.568M Est

Myriad Genetics Announces Expanded Availability Of Precise MRD To Patients Undergoing Treatment And Surveillance For Breast, Colorectal And Renal Cancers

Myriad Genetics Launches Prolaris® + AI, the First Prostate Cancer Test to Combine Genomics and Digital Pathology Artificial Intelligence (AI)

Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)

Actress Jackie Tohn Got Results Nobody Wants But They May Have Saved Her Life

Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock

Myriad Genetics, Inc. 2026 Q1 - Results - Earnings Call Presentation

Myriad Genetics to Participate in Upcoming Investor Healthcare Conferences

TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $6

Myriad Genetics, Inc. Q1 2026 Earnings Call Summary

Wells Fargo Maintains Equal-Weight on Myriad Genetics, Lowers Price Target to $5.5

Myriad Genetics Q1 Earnings Call Highlights